Log in to save to my catalogue

Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retro...

Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retro...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0bbcd42c11e74cbfb91361945db11f28

Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

About this item

Full title

Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Publisher

SAGE Publishing

Journal title

Therapeutic advances in medical oncology, 2022-06, Vol.14

Language

English

Formats

Publication information

Publisher

SAGE Publishing

More information

Scope and Contents

Contents

Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET ) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospe...

Alternative Titles

Full title

Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_0bbcd42c11e74cbfb91361945db11f28

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0bbcd42c11e74cbfb91361945db11f28

Other Identifiers

E-ISSN

1758-8359

DOI

10.1177/17588359221103206

How to access this item